Analysis of surgical interruption of the enterohepatic circulation as a treatment for pediatric cholestasis
2016 · Hepatology · 86 citations
https://doi.org/10.1002/hep.29019
D
Douglas Mogul
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
98
Papers
1.5K
Citations
22
h-index
44
i10-index
Douglas Mogul is an academic researcher from SciClone Pharmaceuticals (United States). The author has contributed to research in topics: Pediatric Hepatobiliary Diseases and Treatments & Hepatitis B Virus Studies & Liver Disease Diagnosis and Treatment. The author has an h-index of 22, co-authored 84 publications.
ORCID: 0000-0002-6486-3302Papers by this author
worksEvent-free survival of maralixibat-treated patients with Alagille syndrome compared to a real-world cohort from GALA
2023 · Hepatology · 30 citations
https://doi.org/10.1097/hep.0000000000000727
Language impairment in adults with end-stage liver disease: application of natural language processing towards patient-generated health records
2019 · npj Digital Medicine · 17 citations
https://doi.org/10.1038/s41746-019-0179-9
Liver simulated allocation model does not effectively predict organ offer decisions for pediatric liver transplant candidates
2021 · American Journal of Transplantation · 10 citations
https://doi.org/10.1111/ajt.16621
Maralixibat Reduces Serum Bile Acids and Improves Cholestatic Pruritus in Adolescents With Alagille Syndrome
2025 · Liver International · 5 citations
https://doi.org/10.1111/liv.16201
THU-094 Clinical benefits with maralixibat for patients with Alagille syndrome are durable through 7 years of treatment: data from the MERGE study
2024 · Journal of Hepatology · 0 citations
https://doi.org/10.1016/s0168-8278(24)01081-x
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat